Anocca AB
anocca.com
Actively hiring
Cell & Gene Therapy
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$126.8M
4 rounds on record
Latest round
$41.8M
Venture round · Aug 2025 · 13 mo ago
Grants
$150k
1 grant · CORDIS
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 17, 2025
Raised a round Venture round $41.8M
May 30, 2023
Raised a round Venture round $38M
Jul 22, 2021
Raised a round Series B $47M · FinanzNachrichten.de
Sep 1, 2017
Won a grant $150k · CORDIS
2014
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2025 | $41.8M | — | businesswire.com |
| Venture round | May 2023 | $38M | — | streetinsider.com |
| Series B | Jul 2021 | $47M | — | FinanzNachrichten.de |
| Grant | Sep 2017 | $150k | — | CORDIS |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Designer cell therapies for pets first and their people next.
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Pioneering Cell Therapies for the Central Nervous System. We are a Salt Lake City-based biotechnology company developing novel macrophage…
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
OverT is redefining what's possible with programmed, off-the-shelf cell therapies and biologics.
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
News
Report
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte's Flow Electroporation Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapiesROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company p
Read more
Report
Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
Largest Facility in Nordics for Clinical Supply of Cell TherapiesSÖDERTALJE, Sweden, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced it has received a certificate of good manufacturing practice (GMP) com
Read more
Report
Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy
Financing from renowned Nordic investors Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of
Read more
Report